---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-075722"
form_type: "8-K"
ticker: "NRXP"
cik: "0001719406"
company_name: "NRX Pharmaceuticals, Inc."
filed_at: "2024-06-27T23:59:59+00:00"
generated_at: "2026-06-01T01:04:07.910503+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Alvogen terminates NRX-101 pact; NRx eyes accelerated FDA filing

## Summary
- Alvogen terminated exclusive development and license agreement for NRX-101 effective June 21, 2024.
- Alvogen claims $4,502,705 in advanced amounts; parties to negotiate royalty within 30 days.
- NRx plans Accelerated Approval filing this year for suicidal bipolar depression, citing trial data.
- Company continues NDA submission for intravenous ketamine (NRX-100) in 2024.
- NRx estimates $3.7B addressable market for NRX-101 in high-risk patients without viable alternatives.

## SEC filing metadata
- accession: 0001104659-24-075722
- form_type: 8-K
- ticker: NRXP
- cik: 0001719406
- company_name: NRX Pharmaceuticals, Inc.
- filed_at: 2024-06-27T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719406/000110465924075722/0001104659-24-075722-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719406/000110465924075722/tm2418373d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-075722
- JSON: https://secwatch.observer/filing/0001104659-24-075722.json
- Plain text: https://secwatch.observer/filing/0001104659-24-075722.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.